Obesity 28 , 529536 (2020)
A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells
doi: 10.3389/fendo.2022.970439 67 AbolhassaniNWinterfeldUKaplanYCJaquesCMinder WyssmannBDel GiovaneCet al
Onoe, K
What You Should Know: PatchMD, a pioneer in transdermal nutrient delivery, has unveiled its new GLP-1 Support Patch Collection, designed to provide essential support for individuals using GLP-1 receptor agonist medications such as Ozempic, Wegovy, and Mounjaro for weight management
STEP 5 Two-Year Safety Results In the STEP 5 trial involving 304 participants (152 receiving semaglutide, 152 receiving placebo), gastrointestinal adverse events occurred in 82.2% of the semaglutide group versus 53.9% of the placebo group over the two-year period